- US-listed companies
- Sonnet BioTherapeutics Holdings, Inc.
- Income statement
Sonnet BioTherapeutics Holdings, Inc. (SONN) Income statement
Market cap
$1.26
P/E ratio
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/09 | 2021/09 | 2022/09 | 2023/09 | 2024/09 | 2025/09 | |
| Revenue | 1 | 7 | 8 | 30 | 42 | 42 | 41 | 41 | 30 | - | 483,626 | 349,943 | 0 | 18,626 | 1 |
| Revenue growth (%) | - | - | - | ||||||||||||
| Research & development | - | - | - | - | - | - | - | - | - | 10 | - | 21 | 12 | 6 | 8 |
| Operating margin (%) | - | ||||||||||||||
| Operating expenses | 2 | 10 | 13 | 35 | 54 | 44 | 47 | 46 | 46 | - | 26 | 30 | 19 | 12 | 17 |
| Operating income | -714,305 | -2,869,865 | -4,606,355 | -5,544,308 | -11,487,916 | -2,619,888 | -5,235,377 | -5,355,101 | -16,078,222 | -24,237,772 | -25,087,436 | -29,669,359 | -18,792,617 | -11,849,471 | -15,844,115 |
| Income before tax | -1,094,208 | -3,375,328 | -5,287,094 | -6,202,374 | -14,321,425 | -4,147,571 | -6,794,771 | -7,900,491 | -17,369,632 | - | - | - | - | - | -15,793,087 |
| Pretax margin (%) | -74.8 | -49 | -64.1 | -20.8 | -33.8 | -9.9 | -16.4 | -19.5 | -57.6 | - | - | - | - | - | -1,579.3 |
| Provision for income taxes | 14,608 | 19,205 | 40,935 | -476,501 | 187,568 | 198,463 | -644,429 | -701,224 | 73,726 | - | - | - | - | - | 218,400 |
| Effective tax rate (%) | - | - | - | - | - | ||||||||||
| Net income | -1,103,390 | -3,166,565 | -5,214,119 | -5,725,873 | -12,136,526 | -9,076,572 | -6,794,771 | -6,854,420 | -17,726,384 | -24,265,115 | -24,983,961 | -29,721,841 | -18,832,694 | -7,437,232 | -16,011,487 |
| Net income margin (%) | - | ||||||||||||||
| Earnings per share | - | - | - | -0.87 | -0.86 | - | - | - | - | - | - | -6.84 | -18.14 | -11.35 | -3.95 |
| Diluted EPS | - | - | - | -0.15 | - | - | - | - | - | - | - | -6.84 | -18.14 | -11.35 | -3.95 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | ||||
| EBITDA margin (%) | - | - | - | - | - | - | - | - | - | - | - |